Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Ikena Oncology, Inc. (Nasdaq: IKNA) announced the closure of its initial public offering (IPO) on 8,984,375 shares of common stock at a price of $16.00 per share, raising approximately $143.8 million in gross proceeds. The offering included the full exercise of the underwriters' option for an additional 1,171,875 shares. Jefferies, Cowen, Credit Suisse, and William Blair served as joint book-running managers. Ikena focuses on cancer therapies targeting critical signaling pathways and has five development programs, including collaborations with Bristol-Myers Squibb.
- Raised approximately $143.8 million from the IPO.
- The offering included the full exercise of the underwriters' option for additional shares.
- Ikena is advancing five oncology programs, indicating potential for growth.
- None.
Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the closing of its initial public offering of 8,984,375 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,171,875 additional shares of common stock, at a public offering price of
Jefferies, Cowen, Credit Suisse and William Blair acted as joint book-running managers for the offering.
The registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and became effective on March 25, 2021. The offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@Jefferies.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at usa.prospectus@credit-suisse.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ikena Oncology
Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005881/en/
FAQ
What was the purpose of Ikena's IPO on Nasdaq under the symbol IKNA?
How much did Ikena Oncology raise from its initial public offering?
Who were the underwriters for Ikena's IPO?
What are Ikena's key product candidates mentioned in the press release?
